Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation

Zeléfsky, Michael J.; Kuban, Deborah A.; Levy, L.B.; Potters, Louis; Beyer, David; Blasko, John C.; Moran, Brian; Ciezki, Jay P.; Zietman, Anthony L.; Pisansky, Thomas M.; Elshaikh, Mohamed A.; Horwitz, Eric M.

doi:10.1016/j.ijrobp.2006.08.056

Cited by 433 publications

(242 citation statements)

References 11 publications

Supporting

Mentioning

208

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3] The biochemical control rates observed are significantly better with high-dose radiation compared with conventional doses. However, most men who fail EBRT receive androgen-deprivation therapy, which can have an impact on quality of life and cardiac, metabolic, and bone health.…”

Section: Introductionmentioning

confidence: 99%

Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy

Ahmed

Cathcart

McCartan

et al. 2012

Cancer

View full text Add to dashboard Cite

BACKGROUND:The objective of this study was to evaluate the safety, feasibility, side-effect profile, and proof of concept for focal salvage therapy using high-intensity focused ultrasound (HIFU). METHODS: A registry-based analysis was conducted between 2004 and 2009 of 430 patients who underwent HIFU. Thirty-nine patients received focal salvage therapy for localized recurrence after external beam radiotherapy. Multiparametric magnetic resonance imaging studies combined with transperineal template prostate mapping biopsies or transrectal biopsies were used to localize disease. Validated questionnaires were used to assess functional outcomes. Biochemical failure was defined by using both Phoenix criteria (prostate-specific antigen [PSA] nadir plus 2 ng/mL) and Stuttgart criteria (PSA nadir plus 1.2 ng/mL). RESULTS: The mean pre-HIFU PSA level was 4.6 ng/mL. The median follow-up was 17 months (interquartile range, 10-29 months). International Index of Erectile Function-5 scores decreased from a median AE standard deviation (SD) of 18 AE 16 to 13 AE 21 at 6 months, demonstrating worsening function. Scores on the University of California Los Angeles-Expanded Prostate Cancer Index Composite Urinary domain indicate that pad-free, leak-free continence status was 64%, and the pad-free rate was 87.2% at last follow-up. One rectourethral fistula occurred and spontaneously resolved with urinary and bowel diversion. The actuarial progression-free survival rate (including PSA nonresponders) was 69% at 1 year and 49% at 2 years according to Phoenix criteria. Excluding PSA nonresponders, these rates were 74% and 58%, respectively (Phoenix criteria). CONCLUSIONS: The results from this study indicated that focal salvage therapy is a potential strategy for localized recurrence after radiotherapy that may reduce the harms resulting from whole-gland salvage therapies. Cancer 2012;118:4148-55. V C 2012 American Cancer Society.KEYWORDS: focal, salvage, high-intensity focused ultrasound, prostate cancer, external beam radiotherapy. INTRODUCTIONBiochemical failure in men who have undergone external beam radiation therapy (EBRT) for localized prostate cancer can occur in approximately 10% to 30%. 1-3 The biochemical control rates observed are significantly better with high-dose radiation compared with conventional doses. However, most men who fail EBRT receive androgen-deprivation therapy, which can have an impact on quality of life and cardiac, metabolic, and bone health. 4,5 However, many patients have localized disease that may be suitable for local salvage therapy using surgery, brachytherapy, cryotherapy, or high-intensity focused ultrasound (HIFU). Those who undergo whole-gland salvage therapy have a significant risk of genitourinary and bowel complications, because the viability of surrounding tissues may have been compromised by previous radiation. The biochemical cancer control rates that result from these salvage therapies are on the order of 40% to 60% over 2 to 5 years follow-up. [6][7][8] We previously reported our early res...

show abstract

Section: Introductionmentioning

confidence: 99%

Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy

Ahmed

Cathcart

McCartan

et al. 2012

Cancer

View full text Add to dashboard Cite

show abstract

“…They found that a nPSA <0.5ng/ml was associated with up to 92 per cent PSA relapse-free survival at eight years follow-up. 25 Khaksar et al used both the three consecutive PSA rises and the nadir + 2 definitions of biochemical failure: a nPSA <0.5ng/ml was a suitably representative target. 26 Zelefsky et al used an arbitrary nPSA at three years after treatment.…”

Section: Psa Post-brachytherapymentioning

confidence: 99%

“…26 Zelefsky et al used an arbitrary nPSA at three years after treatment. 25 The definition of the nPSA following brachytherapy is complicated by the phenomenon of the PSA bounce. It is characterised by a PSA rise followed by a decay in PSA to the original level or below.…”

Section: Psa Post-brachytherapymentioning

confidence: 99%

Interpretation of PSA levels after radical therapy for prostate cancer

Goonewardene

Phull²,

Bahl³

et al. 2014

Trends Urol & Men's Health

View full text Add to dashboard Cite

show abstract

“…It has been proven to be as effective as surgery or external beam radiotherapy 1. In China, permanent seed implants have also been used in the treatment of primary and recurrent tumors of the head and neck, lungs, liver, pancreas, rectal, gynecological, and soft tissue 2, 3, 4, 5, 6, 7, 8, 9.…”

Section: Introductionmentioning

confidence: 99%

“…Both the clinical outcome and side effects of seed implantation depend on the dose to the tumor and organs at risk (OARs). Zelefsky et al1 found that patients, where the 125 I dose to 90% of the prostate (D 90 ) was > or = 130 Gy, the 8‐year prostate‐specific antigen (PSA) relapse‐free survival was 93% compared with 76% for those with lower D 90 dose levels ( P < 0.001). Stock et al10 found that the optimal dosimetry of 125 I seed implantation is D 90 between 140 and 180 Gy for prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

Dosimetric characterization of GMS BT‐125‐1 ¹²⁵I radioactive seed with Monte Carlo simulations and experimental measurement

Zhao

Yang

Ren

et al. 2017

J Applied Clin Med Phys

View full text Add to dashboard Cite

PurposeTo investigate the dosimetric characteristics of the new GMS BT‐125‐1 125I radioactive seed, including dose rate constant, radial dose functions, and anisotropy functions.MethodsDosimetric parameters of GMS BT‐125‐1 125I seed including dose rate constant, radial dose functions, and anisotropy functions were calculated using the Monte Carlo code of MCNP5, and measured with thermoluminescent dosimeters (TLDs). The results were compared with those of PharmaSeed BT‐125‐1, PharmaSeed BT‐125‐2 125I, and model 6711 125I seeds.ResultsThe dose rate constant of GMS BT‐125‐1 125I seed was 0.959 cGy·h−1·U−1, with the difference of 0.94%, 0.83%, and 0.73% compared with the PharmaSeed BT‐125‐1 125I seed, PharmaSeed BT‐125‐2 125I seed, and Model 6711 125I seed, respectively. For radial dose function, the differences between the Monte Carlo and the experimental g(r) results were mostly within 10%. Monte Carlo results of g(r) for GMS BT‐125‐1 125I seed were found in agreement (within 3.3%) with corresponding results for the PharmaSeed BT‐125‐2 125I seed. The largest differences were 8.1% and 6.2% compared with PharmaSeed BT‐125‐1 125I seed and model 6711 125I seed, respectively. For anisotropy function, the difference between GMS BT‐125‐1 125I seed and PharmaSeed BT‐125‐2 125I seed was typically <10%.ConclusionsThe measured dose rate constant, radial dose functions, and two‐dimensional anisotropy functions for the GMS BT‐125‐1 125I seed showed good agreement with the Monte Carlo results. The dose rate constant of the GMS BT‐125‐1 125I seed is similar to that of the PharmaSeed BT‐125‐1 125I seed, the PharmaSeed BT‐125‐2 125I seed, and the model 6711 125I seed. For radial dose functions and two‐dimensional anisotropy functions, the GMS BT‐125‐1 125I seed is similar to the PharmaSeed BT‐125‐2 125I seed but different from the PharmaSeed BT‐125‐1 125I seed and the model 6711 125I seed.

show abstract

Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation

Cited by 433 publications

References 11 publications

Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy

Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy

Interpretation of PSA levels after radical therapy for prostate cancer

Dosimetric characterization of GMS BT‐125‐1 ¹²⁵I radioactive seed with Monte Carlo simulations and experimental measurement

Contact Info

Product

Resources

About

Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation

Cited by 433 publications

References 11 publications

Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy

Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy

Interpretation of PSA levels after radical therapy for prostate cancer

Dosimetric characterization of GMS BT‐125‐1 125I radioactive seed with Monte Carlo simulations and experimental measurement

Contact Info

Product

Resources

About

Dosimetric characterization of GMS BT‐125‐1 ¹²⁵I radioactive seed with Monte Carlo simulations and experimental measurement